MAP2K7 and neoplasm: Importantly, the observed differences in responses to KRASG12C and MEK inhibitors, as well as the varying immune profiles across subtypes, suggest opportunities for rational combination therapies—such as combining KRASG12C inhibitors with immune checkpoint blockade in the immunogenic KC2 subtype, or co‐targeting NE features and the MEK pathway in KC1 tumours.